Stockscreener 앱 받기
33.43
0.59%
-0.20
시간 외 거래:
33.43
전일 마감가:
$33.63
열려 있는:
$33.57
하루 거래량:
865.06K
Relative Volume:
0.69
시가총액:
$2.57B
수익:
$13.17M
순이익/손실:
$-199.06M
주가수익비율:
-12.20
EPS:
-2.74
순현금흐름:
$-156.53M
1주 성능:
+9.61%
1개월 성능:
+6.40%
6개월 성능:
-14.74%
1년 성능:
-18.48%
1일 변동 폭
$32.84
$33.87
1주일 범위
$30.65
$36.68
52주 변동 폭
$26.74
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
명칭
Xenon Pharmaceuticals Inc
전화
(604) 484-3300
주소
200 - 3650 GILMORE WAY, BURNABY
XENE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
33.43 | 2.63B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-01-04 | 개시 | Citigroup | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-04-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-14 | 개시 | Goldman | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-10-19 | 개시 | Raymond James | Outperform |
| 2022-08-29 | 개시 | BofA Securities | Buy |
| 2022-07-21 | 개시 | JP Morgan | Overweight |
| 2021-10-28 | 개시 | RBC Capital Mkts | Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-07-21 | 개시 | Needham | Buy |
| 2020-06-01 | 재개 | Jefferies | Buy |
| 2020-03-25 | 개시 | Wedbush | Outperform |
| 2020-01-08 | 개시 | William Blair | Outperform |
| 2019-09-20 | 개시 | Guggenheim | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2017-03-13 | 개시 | Jefferies | Buy |
| 2016-10-21 | 개시 | Stifel | Buy |
| 2016-09-26 | 개시 | Guggenheim | Buy |
| 2016-04-14 | 재확인 | Jefferies | Buy |
| 2015-10-30 | 재개 | Jefferies | Buy |
| 2014-12-02 | 개시 | Canaccord Genuity | Buy |
모두보기
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
Xenon Pharma Q2 2025 Earnings Preview - MSN
Xenon Pharmaceuticals Inc. stock trendline breakdownHigh Yield Signals with Entry Timing - Newser
Momentum divergence signals in Xenon Pharmaceuticals Inc. chartFree Stock Portfolio Allocation Guidance - Newser
Xenon Pharmaceuticals XENE 2025Q2 Earnings Preview Upside Potential on Innovative Product Launches - AInvest
Xenon Pharmaceuticals Inc expected to post a loss of 99 cents a shareEarnings Preview - TradingView
Fund Update: GEODE CAPITAL MANAGEMENT, LLC added 900,746 shares of XENON PHARMACEUTICALS ($XENE) to their portfolio - Quiver Quantitative
Will Xenon Pharmaceuticals Inc. continue its uptrendMonthly Trade Result and Signal Summary - Newser
Measuring Xenon Pharmaceuticals Inc.’s beta against major indicesFree Stable Entry High Return Opportunities - Newser
Xenon Pharmaceuticals Skyrockets 8.9%—What’s Fueling This Biotech Breakout? - AInvest
Xenon Pharmaceuticals to Announce Q2 2025 Financial Results - The Globe and Mail
Signal strength of Xenon Pharmaceuticals Inc. stock in tech scannersEntry Confirmation Using Short-Term Forecasting - Newser
Is Xenon Pharmaceuticals Inc. stock poised for growthFree Target Return Focused Trade Insights - Newser
Xenon Pharmaceuticals Announces Q2 2025 Financial Results and Business Update - AInvest
Why Xenon Pharmaceuticals’ Stock is Gaining Attention - TipRanks
Xenon Pharmaceuticals Inc. to Report Q2 2025 Financial Results and Business Update on August 11, 2025 - Quiver Quantitative
Xenon to Report Q2 2025 Financial Results on August 11, 2025 - GlobeNewswire
Xenon Pharmaceuticals Sets Q2 Earnings Date: Key Updates Expected on Epilepsy Drug Azetukalner - Stock Titan
Will a bounce in Xenon Pharmaceuticals Inc. offer an exitMulti-Year Signal Summary and Entry Timing - Newser
Identifying reversal signals in Xenon Pharmaceuticals Inc.Sector-Wise Stock Strength Trend Analysis - Newser
Why is Xenon Pharmaceuticals Inc. stock attracting strong analyst attentionUnlock market-leading stock analysis - Jammu Links News
Using economic indicators to assess Xenon Pharmaceuticals Inc. potentialFree Weekly Potential Breakout Stock List - Newser
What drives Xenon Pharmaceuticals Inc. stock priceGet professional guidance for market timing - Jammu Links News
Xenon Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayPortfolio Risk Distribution Analysis Tool - Newser
What are the latest earnings results for Xenon Pharmaceuticals Inc.Discover the fastest growing stocks today - Jammu Links News
When is Xenon Pharmaceuticals Inc. stock expected to show significant growthUnlock exclusive stock market insights - Jammu Links News
How does Xenon Pharmaceuticals Inc. compare to its industry peersFree Daily Trading Room Entry - Jammu Links News
What catalysts could drive Xenon Pharmaceuticals Inc. stock higher in 2025Capitalize on market trends before they peak - Jammu Links News
What is Xenon Pharmaceuticals Inc. company’s growth strategyRapid growth opportunities - Jammu Links News
Is Xenon Pharmaceuticals Inc. a good long term investmentBuild wealth with proven stock investing tactics - Jammu Links News
What’s the recovery path for long term holders of Xenon Pharmaceuticals Inc.Free Fundamental + Technical Hybrid Stock Tips - Newser
Xenon Pharmaceuticals Inc. Stock Analysis and ForecastCapitalize on market momentum for profits - Jammu Links News
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Federated Hermes Inc. - Defense World
Using data tools to time your Xenon Pharmaceuticals Inc. exitFree Oversold Recovery Opportunity Stocks - Newser
Is Xenon Pharmaceuticals Inc. still worth holding after the dipAI Trend Detection for Entry Timing - Newser
Is a relief rally coming for Xenon Pharmaceuticals Inc. holdersFree Accurate Technical Trend Reversal Picks - Newser
Is it the right time to buy Xenon Pharmaceuticals Inc. stockGain access to exclusive stock analysis - Jammu Links News
What is the dividend policy of Xenon Pharmaceuticals Inc. stockUnlock expert market analysis instantly - Jammu Links News
Is Xenon Pharmaceuticals Inc. stock overvalued or undervaluedFree Stock Market Knowledge Sharing - Jammu Links News
How volatile is Xenon Pharmaceuticals Inc. stock compared to the marketBreakneck growth rates - Jammu Links News
Xenon Pharmaceuticals Issues Equity Inducement Grants to New Employees - The Globe and Mail
Xenon Pharmaceuticals Inc. stock trend forecastSafe Investment Ideas with Growth Upside - Newser
Assetmark Inc. Has $669,000 Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Short Interest Update - Defense World
Visual analytics tools that track Xenon Pharmaceuticals Inc. performanceTechnical Screener for High Growth Stocks - Newser
Has Xenon Pharmaceuticals Inc. found a price floorRisk Managed Watchlist with Breakout Picks - Newser
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xenon Pharmaceuticals Expands Team: Grants $739K in Stock Options to 6 New Hires - Stock Titan
Envestnet Asset Management Inc. Sells 4,447 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Can you recover from losses in Xenon Pharmaceuticals Inc.Free Entry Zone Strategy for Consistent Profit - Newser
Why Xenon Pharmaceuticals Inc. stock attracts strong analyst attentionTrend Confirmation Scanner with Entry Focus - Newser
Xenon Pharmaceuticals Inc (XENE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):